HomeHealth articlesangiosarcomaHow Can We Treat Dabska Tumor?

Dabska Tumor - Causes, Clinical Appearence, and Treatment

Verified dataVerified data
0

3 min read

Share

Dabska tumor is a rare low-grade tumor that develops in blood vessels in or under the skin. It is also called papillary intra-lymphatic angioendothelioma.

Written by

Dr. Y Gayathri

Medically reviewed by

Dr. Rajesh Gulati

Published At October 12, 2022
Reviewed AtMay 17, 2023

Dabska tumor, a low-grade angiosarcoma, often affects the skin and subcutaneous tissues. It is commonly found in children. It is a rare type of hemangioendothelioma, distinguished by the presence of intraluminal papillary endothelial structures. It is often congenital or may sometimes grow from a pre-existing benign vascular lesion. Most of the tumors develop superficial, but some may develop in deeper tissues also.

Dabska tumor was first originally described by Maria Dabska in the year of 1969 by presenting six patients in a 14-year duration of study. She was working at Maria Sklodowska-Curie oncology institute in Poland. There, she was a member of the pathology department. Maria Dabska named this tumor endovascular papillary angioendothelioma of the skin. Since it was first described, there have been only 30 case reports presenting Dabska tumors with varying patterns.

Enzinger and Weiss termed the Dabska tumor as a low-grade angiosarcoma occurring in the skin and subcutis of infants. Although this tumor is rare in adults, few cases have been reported by younger adults.

How Is Dabska Tumor Caused?

  • The cause of the Dabska tumor is yet to be found. There were not many cases reported till now; hence, the etiology is still unknown. There are no risk factors identified till now.

  • Few studies have been conducted recently suggesting that there is lymphatic differentiation. It is viewed as intralymphatic neoplasia. This tumor is similar to that of retiform hemangioendothelioma.

  • Due to its similarity, the histogenic relationship is assumed. Retiform hemangioendothelioma might be an adult form of the Dabska tumor. This tumor can be classified under hemangioendothelioma since it is a neoplasm of blood vessels. It displays behavior varying from benign hemangiomas to malignant angiosarcomas.

  • Tumor marker studies of Dabska tumors suggest that these tumors are lymphangiomas and not angiosarcoma due to the identification of lymphatic endothelial cell marker vascular endothelial cell growth factor 3.

  • Frequency and race are not yet established due to the lesser number of cases reported now. It is more commonly found in children than in adults.

What Does a Dabska Tumor Look Like?

  • It is a slow-growing tumor that develops into a nodule within the layers of the skin.

  • It can grow up to 40 cm in size.

  • It is asymptomatic.

  • It is localized to subcutaneous tissues of extremities and dermis.

  • Few tumors are poorly circumscribed.

  • Few tumors show surface nodularity with ulceration.

  • Rarely do Dabska tumors have satellite nodules.

  • The color of the tumor may vary. It can be pink, violet, or blue.

  • Dabska tumor has atrophic dermis.

  • It can occur anywhere in the body.

  • Commonly found on the head and extremities.

  • Other areas of the body where Dabska tumors can develop are the neck, trunk, tongue, cheeks, palms, heels, buttocks, brain, spleen, bone, and testis.

  • Few Dabska tumors are observed to be associated with the degeneration of underlying vascular tumors.

  • Rarely, Dabska tumors are painful, ulcerate, and cause bleeding.

  • Symptomatic tumors are often associated with regional nodal involvement and pulmonary metastasis.

What Is the Histological Appearance of Dabska Tumor?

Diagnosis of a Dabska tumor is often a challenging one due to its rarity, multifocality, and morphological differentiation. Confirmation of diagnosis of Dabska tumor is possible only by biopsy followed by laboratory investigation. The specimen that is collected is sent to a laboratory for immunohistochemistry studies and histopathological examination.

  • Dabska tumors are present in the dermis and/or subcutaneous tissues. They are characterized by numerous interconnecting vascular channels with papillary tufts. These vascular channels are lined by endothelial cells forming a hobnail or matchstick appearance, assuming a focal pattern of rosettes.

  • The nucleus of the cells is apically placed, giving rise to a surface bulge.

  • The tumor shows moderate mitotic activity. It shows a high nuclear-to-cytoplasmic ratio.

  • It also shows intravascular and perivascular infiltrates.

  • The finding that helps in distinguishing Dabska tumors is papillary projections. The tumor shows intraluminal lymphocytes attached to endothelial cells.

  • Immunohistochemistry shows that tumor cells react positively to vascular and lymphatic markers.

  • It is positive for the lymphatic endothelial marker, D2-40, and Factor VIII-related antigen.

  • Dabska tumor shows positive reactivity for CD31, CD34, and CD68.

  • It displays a positive reaction for alpha-smooth muscle action.

  • Under an electron microscope, small granules consisting of Von Willebrand factor and P-selectin are called Weibel-Palade bodies.

  • Electron microscopy also reveals the presence of pinocytotic vesicles and cells with irregular nuclei rich in perinuclear cytoplasmic filaments.

  • Hyaline globules with electron-dense basement membranes are also found.

What Is the Treatment for Dabska Tumor?

Wide local excision is the treatment of choice for these vascular tumors. Recurrence after excision is unusual. Though it has a good prognosis, it can be locally invasive and undergo metastatic transformation. If the nodal spread is suspected, lymph node dissection should be conducted.

Conclusion:

Dabska tumor is a rare, low-grade vascular neoplasm found in skin and subcutaneous tissue. It has slow progress with low invasive ability. The outcome of this tumor is good, and the survival rate of patients is luckily high. Once surgical excision is performed, periodic, regular check-ups are suggested to ensure that there is no recurrence or nodal involvement. Long-term clinical follow-up is necessary along with the multi-disciplinary approach to assess the metastatic spread of cancer, if any.

Frequently Asked Questions

1.

How Do You Define Composite Hemangioendothelioma?

A specific form of vascular tumor known as composite hemangioendothelioma shows traits of both benign and malignant. They often appear on or beneath the skin of the arms or legs, although they can also form in the head, neck, or chest areas. Composite hemangioendothelioma normally does not metastasize to distant portions of the body, yet it may spread to surrounding lymph nodes. After therapy, there is a chance of local recurrence in the same location.

2.

Hemangioendothelioma: Is It Cancerous or Benign?

The term "hemangioendothelioma" refers to a type of vascular neoplasm that demonstrates a biological behavior between completely benign hemangiomas and very malignant angiosarcomas. These tumors are distinguished by their vascular origin and the involvement of endothelial cells in their development.

3.

How Is Hemangioendothelioma Treated?

Surgery is the main treatment for hemangioendothelioma (EHE) when it is localized and has not spread to other body parts. Surgery may be paired with chemotherapy and radiation therapy to increase the effectiveness of the treatment. In addition, depending on the specifics of each case, medical professionals may utilize radiation therapy as a stand-alone treatment for hemangioendothelioma, either with or without surgery. 

4.

What Percentage of Hemangioendothelioma Patients Survive?

The one, three, and five-year cumulative survival rates as per the current research were 96.2 percent, 87 percent, and 75.3 percent, respectively.

5.

What Is the Fatality Rate of Hemangioendothelioma?

As per studies conducted, it has been estimated that the death rate for soft-tissue epithelioid hemangioendothelioma is between 13 percent and 18 percent. 

6.

Does Hemangioendothelioma Pain?

Hemangioendothelioma can result in discomfort. However, the location and intensity of the pain can differ based on a number of variables, including the size, position, and closeness of the tumor to other structures. 

7.

What Causes Epithelioid Hemangioendothelioma to Recur?

Epithelioid hemangioendothelioma can recur due to various reasons like incomplete resection and metastasis. Recurrence can also occur due to variations in response to the treatment plan. 

8.

What Are the Indicators of Epithelioid Hemangioendothelioma?

Nearly all Epithelioid Hemangioendothelioma patients have the WWTR1-CAMTA1 gene fusion caused by a t(1;3) (p36;q25) translocation. Vascular markers, including CD31, CD34, FLI1, and ERG, are expressed by the tumor cells of Epithelioid Hemangioendothelioma.

9.

What Is a Vascular Congenital Benign Tumour?

Vascular tumors are benign tumors brought on by dividing endothelial cells. These lesions can appear on any site, develop postnatally, and manifest during infancy or childhood.

10.

How Is Hepatic Epithelioid Hemangioendothelioma Treated?

Hepatic epithelioid hemangioendothelioma within the liver has been treated with transcatheter arterial chemoembolization. Surgical resection is the most effective course of action for a single tiny hepatic Epithelioid Hemangioendothelioma.

11.

How Do You Define Retiform Hemangioendothelioma?

Retiform hemangioendothelioma is an uncommon, slow-growing tumor that often develops on or beneath the arms, legs, and trunk skin. Blood vessels in the tumor are arranged in a tree-like pattern. In addition to spreading to surrounding tissue, retiform hemangioendothelioma frequently recur following therapy. Most of the time, they do not spread to other bodily areas.

12.

What Is the Etiology of Epithelioid Hemangioendothelioma?

Malignant tumors, such as epitheloid hemangioendothelioma (EHE), develop when a healthy cell transforms into a cancer cell that grows uncontrollably. Researchers have identified the specific genetic mutation that causes EHE. One gene connects to another gene due to the abnormal joining of two chromosomes. These genes are CAMTA1 and WWTR1, sometimes referred to as TAZ. The union of WWTR1 and CAMTA1 brings on EHE.

13.

What Fuses in Epitheliod Hemangioendothelioma?

The fusion of the WWTR1 and CAMTA1 genes characterizes the uncommon vascular tumor known as epithelioid hemangioendothelioma. About 90 percent of EHE patients had this fusion, a defining molecular feature of the illness. 

14.

How Is Epithelioid Sarcoma Like Hemangioendothelioma Defined?

Epithelioid sarcoma-like hemangioendothelioma (ESHE) is a very rare tumor that often manifests as nodules in the distal extremities of young people. It can form in both soft tissue and bone. The nodules have the uncommon trait of concurrently crossing several tissue planes, including the dermis, subcutis, skeletal muscle, and bone.
Source Article IclonSourcesSource Article Arrow
Dr. Rajesh Gulati
Dr. Rajesh Gulati

Family Physician

Tags:

dabska tumorangiosarcoma
Community Banner Mobile
By subscribing, I agree to iCliniq's Terms & Privacy Policy.

Source Article ArrowMost popular articles

Do you have a question on

angiosarcoma

Ask a doctor online

*guaranteed answer within 4 hours

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.

This website uses cookies to ensure you get the best experience on our website. iCliniq privacy policy